Market Overview

UPDATE: JP Morgan Upgrades Charles River Laboratories to Overweight on Risk/Reward

Share:
Related CRL
Lightning Round: Jim Cramer Advises His Viewers On Mallinckrodt, GoPro And More
Earnings Scheduled For November 9, 2017
Opus Point Partners Management, LLC Buys Bioverativ Inc, ACADIA Pharmaceuticals Inc, United ... (GuruFocus)

JP Morgan raised its rating on Charles River Laboratories (NYSE: CRL) from Neutral to Overweight and increased its price target from $40 to $42.

JP Morgan commented, "Charles River Laboratories (CRL) hosted its annual December guidance call yesterday, reiterating 2012 estimates (albeit with some EPS softness) and introducing 2013 bottom-line estimates 4-5% below consensus in light of the AstraZeneca deal (for which costs will be realized before full revenue benefits). While the news was met with disappointment, with shares -9.4%, we now see risk/reward as favorable heading into 2013 given improving fundamentals (3-5% LC growth projected vs. 1% in 2012, negative growth in 2009-2011), continued cost discipline, and importantly, a 10% free cash flow yield."

Charles River Laboratories closed at $35.65 on Wednesday.

Latest Ratings for CRL

DateFirmActionFromTo
Nov 2017JefferiesMaintainsBuy
Nov 2017Bank of AmericaMaintainsBuy
Oct 2017JefferiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!

Partner Center